Related Experiment Video

Updated: Nov 27, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.3K

Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis

Minhua Lin1, Huamin Zeng1, Guiqing Deng2

  • 1Paediatrics School, Guangzhou Medical University, Guangzhou, 511432, China.

Clinics and Research in Hepatology and Gastroenterology
|December 4, 2020
PubMed

Insights

Vitamin E shows potential in improving blood lipids for children with non-alcoholic fatty liver disease (NAFLD). However, its impact on liver function and tissue is unclear, and increased fasting glucose levels require further investigation.

Area of Science:

  • Pediatric Gastroenterology
  • Nutritional Science
  • Metabolic Disorders

Background:

  • Non-alcoholic fatty liver disease (NAFLD) lacks specific pediatric treatments.
  • Emerging evidence suggests vitamin E may offer therapeutic benefits for pediatric NAFLD.

Purpose of the Study:

  • To conduct a meta-analysis evaluating vitamin E's efficacy in treating pediatric NAFLD.
  • To synthesize findings from existing clinical trials on vitamin E for childhood NAFLD.

Main Methods:

  • Systematic search of PubMed, Embase, Scopus, and Cochrane Library databases.
  • Inclusion of trials examining vitamin E treatment for pediatric NAFLD published before March 2020.
  • Meta-analysis of identified studies.

Main Results:

  • Vitamin E significantly reduced low-density lipoprotein (LDL) and total cholesterol (TCHO).
  • No significant improvements were observed in body mass index (BMI), triglycerides (TG), high-density lipoprotein (HLD), fasting insulin, HOMA-IR, liver enzymes (ALT, AST, GGT), or histological features (ballooning, fibrosis).
  • Vitamin E intake for ≤12 months was associated with increased fasting glucose (FSG) levels.

Conclusions:

  • Vitamin E therapy offers partial improvement in blood lipid profiles for pediatric NAFLD.
  • Current evidence does not support a significant impact of vitamin E on liver function or histology in children with NAFLD.
  • The observed increase in FSG levels warrants further research to understand its clinical implications.
Abstract

Keywords:
ChildMeta-analysisNon-alcoholic fatty liver diseaseVitamin E

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

325
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
92
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
86
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
112
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
111
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
138
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
87